Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.
New Haven, CT, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.
Read more about the latest issues in cybersecurity
The Domain Name System Security Extensions (DNSSEC or DNS Security Extensions) is a set of Internet ...
Data is rapidly becoming one of the most valuable assets in the modern world. The digital giants ...
Compare Biohaven Pharmaceuticals's security performance with other companies